secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001641172-25-018398
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA doses first patient in Phase 2 expansion for ateganosine in advanced NSCLC; median OS 17.8 months
--------------------------------------------------------------------------------

- First patient dosed in Taiwan in THIO-101 expansion for 3L NSCLC after CPI/chemo failure.
- Median overall survival of 17.8 months observed in 22 patients (95% CI lower bound 12.5 months) in third-line setting.
- Expansion includes two arms: ateganosine+cemiplimab (Libtayo) and monotherapy; screening in Europe/Asia.
- Regeneron supplies Libtayo for combination cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225018398/0001641172-25-018398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225018398/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-018398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer